Core Viewpoint - Novo Nordisk has lowered its full-year profit forecast, presenting an early challenge for the newly appointed CEO Mike Doustdar as the company faces slowing sales and a rapidly evolving obesity drug market [1] Company Summary - The company is experiencing challenges in its sales performance, which has led to a revision of its profit outlook for the year [1] - The newly appointed CEO, Mike Doustdar, is tasked with navigating these challenges in a competitive and changing market [1] Industry Summary - The obesity drug market is undergoing significant changes, impacting sales dynamics for companies like Novo Nordisk [1] - The slowing sales trend indicates potential shifts in consumer demand or competitive pressures within the obesity treatment sector [1]

UnitedHealth shares plunged 17.4% premarket on Thursday after the insurer dramatically slashed its profit forecast for the year after it revealed disappointing earnings.The healthcare company – whose top insurance executive was shot dead in midtown Manhattan in December – cut its full-year adjusted earnings outlook to a range of $26 to $26.50 per share, down from $29.50 to $30 a share.The firm also reported adjusted income of $7.20 a share in the first quarter, below analysts’ expectations of $7.29, accordi ...